Bio€quity Europe celebrates 25 years

 

Biotech’s Complex Moment: What’s Next for Europe?

Biotech is growing more complex as companies race to source Asian assets for newcos in the West and geopolitical tensions challenge globalization, data sharing and cross-border talent exchange.

What’s next for European biotech? Can it rise to the complexity of the moment? Can it match the growing competition and walk the fine line of geopolitics?

Celebrating its 25th year, Bio€quity Europe is the destination event for biopharma decision-makers to network, partner and debate critical issues facing the biotech industry.

CIC’s, Dr Anne Horgan is joining the “Takeaways from the 25th BioEquity Europe” on 14 May

Wrapping up the 25th BioEquity Europe with a live podcast featuring Editor in Chief Simone Fishburn, Head of BD Joshua Berlin and special guests joining host Stephen Hansen to discuss key takeaways of the three-day event, plus a look ahead to BioCentury’s Grand Rounds-Europe conference in September in Cambridge, U.K.

Session Chair: Stephen Hansen, Director of Biopharma Intelligence, BioCentury Inc.

Panelists:

  • Joshua Berlin, Head of Corporate Alliances & Business Development, BioCentury Inc.
  • Simone Fishburn, Ph.D, VP & Editor in Chief, BioCentury Inc.
  • Anne Horgan, Partner, Cambridge Innovation Capital (CIC)
  • Ksenija Pavletic, Partner, Jeito Capital

Download the full event brochure here.